# Chapter 4: The Therapeutic Arsenal and Its Limits

**Every major modality of intervention, what it can do, what it cannot, and where each one breaks.**

---

## 4.1 Small Molecules

### Mechanism
Small molecules are organic compounds typically <900 Da that modulate protein function by binding active sites, allosteric pockets, or protein-protein interfaces. They follow Lipinski's Rule of Five for oral bioavailability. Mechanisms include enzyme inhibition, receptor agonism/antagonism, ion channel modulation, and targeted protein degradation (PROTACs, molecular glues).

### Scale and Dominance
- **~90% of all drugs ever approved by the FDA are small molecules.** They remain the backbone of pharmacotherapy.
- In 2024, **34 of 50 novel FDA approvals (68%)** were small molecules. In 2025 through mid-October, **25 of 33 (76%)** were small molecules/chemically synthesized drugs.
- The global small molecule drug market exceeds $1 trillion annually.

### Clinical Trial Success Rates
- **Overall probability of approval (Phase I to approval):** ~10-14% across all drug types. For small molecules specifically, the number skews slightly lower than biologics.
- **Phase I to II:** ~52%. **Phase II to III:** ~29% (the critical attrition point). **Phase III to approval:** ~58%.
- **Oncology small molecules:** dismal 3.4% overall success rate from Phase I to approval.
- **Rare disease small molecules:** ~25% overall success rate (orphan drug incentives, smaller trials, clearer endpoints).
- Projects incorporating **biomarkers** achieve ~26% success rates, nearly double the average.

### Development Timeline and Cost
- **Target-to-candidate:** 3-6 years. For every 10,000 compounds screened, perhaps hundreds become hits, tens become leads, and only a handful reach preclinical candidacy. Hit rate from screen to candidate: **~0.01-0.1%**.
- **Hit-to-lead optimization:** 18-24 months (traditional). AI-assisted approaches have compressed this to ~8 months in select cases.
- **Clinical development:** Phase I averages 21.6 months; Phase II, 25.7 months; Phase III, 30.5 months. Total clinical time: ~6-7 years.
- **Full discovery-to-approval:** 10-15 years.
- **Cost per approved drug:** Median $708 million; mean $1.31 billion (including cost of failures and capital). Phase III alone averages ~$350 million.

### Key Recent Advances (2024-2025)
- **Targeted protein degraders (PROTACs/molecular glues):** Multiple candidates in clinical trials. Arvinas' vepdegestrant (ARV-471), a PROTAC targeting estrogen receptor, in Phase III for breast cancer.
- **Covalent inhibitors:** Sotorasib and adagrasib for KRAS G12C -- the first drugs to target the "undruggable" KRAS oncogene.
- **AI-designed molecules:** Insilico Medicine's INS018_055 (for idiopathic pulmonary fibrosis) entered Phase II, having been AI-designed from target identification to candidate in ~18 months.
- **GLP-1 receptor agonists:** Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro) -- small molecule/peptide hybrids that became among the best-selling drugs globally.

### Honest Limitations
1. **The druggable genome is small.** Only ~10-15% of human proteins have conventional small-molecule binding pockets. ~85% of the proteome remains "undruggable" by traditional approaches.
2. **Selectivity is hard.** Off-target binding causes most clinical failures and side effects. Kinase inhibitors, for example, routinely hit dozens of kinases.
3. **Resistance develops.** Cancer cells evolve resistance to targeted therapies within months to years (e.g., EGFR T790M mutations).
4. **Oral bioavailability constraints.** Lipinski's rules exclude many potentially therapeutic chemical spaces. Peptides, macrocycles, and large natural products are largely oral non-starters.
5. **CNS penetration.** The blood-brain barrier excludes >98% of small molecules. Only ~2% of small molecules cross it effectively.
6. **Cannot address gain-of-function or loss-of-function genetics directly** -- they modulate existing protein activity, not the underlying genetic code.

### Key Companies
Pfizer, Roche, Novartis, Merck, AbbVie, Bristol-Myers Squibb, AstraZeneca, Eli Lilly, Johnson & Johnson, Gilead. AI-native: Recursion, Insilico Medicine, Exscientia (acquired by Recursion), Isomorphic Labs.

---

## 4.2 Biologics (Antibodies and Proteins)

### Mechanism
Biologics are large, complex molecules (typically >5,000 Da) produced by living cells. Monoclonal antibodies (mAbs) bind extracellular targets with extraordinary specificity. Other biologics include fusion proteins (e.g., etanercept), bispecific antibodies, antibody-drug conjugates (ADCs), and recombinant proteins (e.g., insulin, erythropoietin).

### Scale and Market
- **Global biologics market:** $417 billion in 2024, projected to exceed $1 trillion by 2035.
- **Antibody drugs alone:** $245.75 billion market in 2024. Monoclonal antibodies account for ~69% of the biologics segment.
- Over **100 mAbs** are FDA-approved.
- **7 of the top 10 best-selling drugs in 2024 were biologics.**

### Blockbusters (2024 Revenue)

| Drug | Target | Indication | 2024 Revenue |
|------|--------|------------|-------------|
| Keytruda (pembrolizumab) | PD-1 | Cancers | $29.5B |
| Dupixent (dupilumab) | IL-4Ra | Eczema, asthma, COPD | $14.1B |
| Skyrizi (risankizumab) | IL-23 | Psoriasis, Crohn's | $11.7B |
| Darzalex (daratumumab) | CD38 | Multiple myeloma | ~$10B |
| Stelara (ustekinumab) | IL-12/23 | Psoriasis, IBD | ~$8B |

### Clinical Trial Success Rates
- Biologics generally show **higher clinical success rates** than small molecules, partly due to better target specificity and the ability to target extracellular proteins.
- Overall Phase I-to-approval for mAbs: **~15-25%** (higher than small molecule average).
- **ADCs** have had a resurgence: Enhertu (trastuzumab deruxtecan) validated the platform, with multiple new ADCs in late-stage trials.

### Honest Limitations
1. **Extracellular targets only.** Antibodies cannot cross the cell membrane. The entire intracellular proteome is invisible to conventional antibodies.
2. **No oral delivery.** Biologics are administered by injection or infusion. This limits patient compliance, requires cold-chain logistics, and increases healthcare costs.
3. **Cold chain dependency.** >85% of biologics require 2-8 degrees C storage. Cold chain breaches are common and can render products ineffective or harmful. This severely limits global access.
4. **Immunogenicity.** Patients can develop anti-drug antibodies (ADAs) that neutralize the therapeutic. Humanized and fully human antibodies reduced but did not eliminate this problem.
5. **Manufacturing complexity.** mAb production requires mammalian cell culture (CHO cells), complex purification, and extensive quality control. Cost of goods has decreased from ~$1,000s/g to $10s-$100s/g, but products are still priced at ~$2,000+/g.
6. **Biosimilar cliff.** Over 55 blockbuster biologics will lose exclusivity in the next decade. AbbVie's Humira, once the world's #1 drug, fell from peak ~$21B revenue to ~$9B in 2024 due to biosimilar competition.
7. **CNS inaccessible.** Antibodies do not cross the blood-brain barrier. Even bispecific approaches using transferrin receptor shuttles achieve only ~1-5% brain penetration.

### CAR-T Cell Therapies (Biologic/Cell Hybrid)

**Approved Products (as of early 2025): 7 FDA-approved CAR-T therapies**

| Product | Target | Indication | Approval |
|---------|--------|------------|----------|
| Kymriah (tisagenlecleucel) | CD19 | B-ALL, DLBCL | 2017 |
| Yescarta (axicabtagene ciloleucel) | CD19 | DLBCL, FL | 2017 |
| Tecartus (brexucabtagene autoleucel) | CD19 | MCL | 2020 |
| Breyanzi (lisocabtagene maraleucel) | CD19 | DLBCL | 2021 |
| Abecma (idecabtagene vicleucel) | BCMA | Multiple myeloma | 2021 |
| Carvykti (ciltacabtagene autoleucel) | BCMA | Multiple myeloma | 2022 |
| Aucatzyl (obecabtagene autoleucel) | CD19 | DLBCL | 2024 |

**Cost reality:**
- **List price: $373,000-$475,000 per dose** (drug cost alone).
- Total cost including hospitalization, conditioning, management of CRS and neurotoxicity: **$500,000-$1,000,000+** per patient.
- Manufacturing turnaround: **16-33 days** from leukapheresis to product delivery.
- Manufacturing success rate: ~87-96% (up to 13% of patients experience manufacturing failure due to sub-optimal cell growth).

**Successes:**
- Complete remission rates of 40-80% in relapsed/refractory blood cancers where no alternative therapy existed.
- Some patients remain in durable remission >5 years.

**Failures and limitations:**
- **Primary resistance in 10-20% of B-ALL patients, ~30% in CD19+ lymphomas.**
- **Solid tumors remain largely impervious.** The immunosuppressive tumor microenvironment, antigen heterogeneity, and T-cell trafficking barriers have yielded low response rates in every solid tumor trial to date.
- **Cytokine release syndrome (CRS)** occurs in 50-90% of patients (Grade 3+ in ~10-25%).
- **Neurotoxicity (ICANS)** in 20-60% of patients.
- **T-cell lymphoma risk:** Rare (~0.04%) but confirmed cases of secondary T-cell malignancies linked to CAR-T, prompting FDA black box warnings.
- **Autologous = no scalability.** Each dose is manufactured from the individual patient's own cells. There is no "off-the-shelf" product on the market yet.

### Key Companies
Roche/Genentech, AbbVie, Regeneron, Sanofi, Amgen, BMS, Johnson & Johnson, AstraZeneca, Merck, Gilead/Kite, Novartis (CAR-T), Legend Biotech/J&J (Carvykti).

---

## 4.3 Antisense Oligonucleotides (ASOs)

### Mechanism
ASOs are short (12-30 nucleotide) synthetic single-stranded DNA or RNA molecules that bind complementary mRNA through Watson-Crick base pairing. They modulate gene expression through: (1) RNase H-mediated mRNA degradation, (2) steric blockade of translation, or (3) splice-switching (forcing inclusion or exclusion of specific exons). Chemical modifications (phosphorothioate backbone, 2'-MOE, 2'-O-methyl, locked nucleic acids, phosphorodiamidate morpholinos) improve stability and pharmacokinetics.

### Approved ASOs (as of 2025)
At least **13 FDA-approved ASOs:**

| Drug | Mechanism | Indication | Year | Route |
|------|-----------|------------|------|-------|
| Fomivirsen (Vitravene) | RNase H | CMV retinitis | 1998 | Intravitreal |
| Mipomersen (Kynamro) | RNase H | Homozygous FH | 2013 | Subcutaneous |
| Nusinersen (Spinraza) | Splice-switch | SMA | 2016 | **Intrathecal** |
| Eteplirsen (Exondys 51) | Exon skip | DMD (exon 51) | 2016 | IV |
| Inotersen (Tegsedi) | RNase H | hATTR polyneuropathy | 2018 | Subcutaneous |
| Golodirsen (Vyondys 53) | Exon skip | DMD (exon 53) | 2019 | IV |
| Viltolarsen (Viltepso) | Exon skip | DMD (exon 53) | 2020 | IV |
| Casimersen (Amondys 45) | Exon skip | DMD (exon 45) | 2021 | IV |
| Tofersen (Qalsody) | RNase H | ALS (SOD1) | 2023 | **Intrathecal** |
| Eplontersen (Wainua) | RNase H | hATTR polyneuropathy | 2023 | Subcutaneous |
| Olezarsen (Tryngolza) | RNase H | Familial chylomicronemia | 2024 | Subcutaneous |
| Donidalorsen | RNase H | HAE | 2025 | Subcutaneous |

### The Intrathecal Problem
Nusinersen (Spinraza) and tofersen require **intrathecal injection via lumbar puncture** -- a needle inserted into the spinal canal. For Spinraza:
- 4 loading doses over 2 months, then maintenance every 4 months **for life**.
- Each administration requires 5 mL of cerebrospinal fluid removal, followed by injection of 12 mg drug over 1-3 minutes.
- Must be performed by healthcare professionals experienced in lumbar puncture.
- In patients with severe SMA and spinal deformities, standard lumbar access may be impossible; cervical puncture becomes the alternative.
- **Annual cost: ~$375,000/year for Spinraza** (compared to Zolgensma's one-time ~$2.1M).

### Ionis Pharmaceuticals Pipeline
Ionis is the dominant ASO platform company:
- **>40 drugs in clinical development** across neurology, cardiology, and rare disease.
- Key pipeline: Pelacarsen (targeting Lp(a) for cardiovascular outcomes; Phase III data expected H1 2026 in the 8,000+ patient Lp(a)HORIZON trial).
- Ionis claims **>$5 billion in potential peak annual revenue** from current pipeline.
- Novel delivery: Bicycle-conjugated ASOs binding transferrin receptor 1, enabling delivery to muscle and potentially across the blood-brain barrier.
- **70+ companies** are now actively developing ASO therapeutics.

### Delivery Challenges
- **Liver is easy.** GalNAc-conjugated ASOs achieve efficient hepatocyte uptake via the asialoglycoprotein receptor. Most subcutaneous ASOs target liver genes.
- **CNS is hard.** Requires intrathecal injection (invasive, repeated, hospital-based). No systemic ASO has been shown to cross the BBB at therapeutic levels in humans.
- **Muscle is hard.** DMD exon-skipping ASOs show modest efficacy partly due to poor muscle uptake. Eteplirsen's approval was controversial -- clinical benefit was marginal and dystrophin restoration minimal (<1% in some studies).
- **Kidney, heart, lung:** Limited delivery to most non-liver tissues from systemic administration.
- **Enzymatic stability** remains a challenge despite chemical modifications; the most advanced chemistries (cEt, LNA) improve potency but can increase hepatotoxicity risk.

### Honest Limitations
1. **Tissue-restricted delivery.** Liver-targeted ASOs work well; everything else is a delivery problem.
2. **Repeated dosing required.** No ASO achieves permanent gene modification. Patients need injections for life.
3. **Route of administration is often invasive.** Intrathecal injection for CNS targets is burdensome and risks infection, headaches, and procedural complications.
4. **Modest efficacy in some contexts.** The DMD exon-skipping ASOs have shown limited clinical benefit despite accelerated approval.
5. **Hepatotoxicity and thrombocytopenia** are class effects that limit dosing.

### Key Companies
Ionis Pharmaceuticals, Biogen (partner), Sarepta Therapeutics (DMD), Roche, AstraZeneca.

---

## 4.4 Gene Therapy

### Mechanism
Gene therapy delivers functional copies of genes into patient cells to correct genetic defects. Two main viral vector platforms:
- **AAV (adeno-associated virus):** Non-integrating, transduces both dividing and non-dividing cells, multiple serotypes with different tissue tropisms (AAV9 for CNS/muscle, AAV8 for liver, AAV2 for retina). Cargo limit: **~4.7 kb** of transgene DNA.
- **Lentiviral vectors:** Integrating retroviruses derived from HIV. Larger cargo (~8 kb). Used for ex vivo gene therapy (cells removed, transduced, returned). Risk of insertional mutagenesis.

### FDA-Approved Gene Therapies
As of November 2025, **46 FDA-approved cell and gene therapy products** total (including CAR-T and cell therapies). In 2024 alone, 13 novel CGT approvals were granted. Key gene therapies:

| Product | Vector | Indication | Year | Price |
|---------|--------|------------|------|-------|
| Luxturna (voretigene neparvovec) | AAV2 | RPE65 retinal dystrophy | 2017 | $850K |
| Zolgensma (onasemnogene abeparvovec) | AAV9 | SMA (type 1) | 2019 | $2.125M |
| Hemgenix (etranacogene dezaparvovec) | AAV5 | Hemophilia B | 2022 | $3.5M |
| Elevidys (delandistrogene moxeparvovec) | AAVrh74 | DMD | 2023 | $3.2M |
| Skysona (elivaldogene autotemcel) | Lentiviral | Cerebral ALD | 2022 | $3.0M |
| Zynteglo (betibeglogene autotemcel) | Lentiviral | Beta-thalassemia | 2022 | $2.8M |
| Lyfgenia (lovotibeglogene autotemcel) | Lentiviral | Sickle cell disease | 2023 | $3.1M |
| Lenmeldy (atidarsagene autotemcel) | Lentiviral | MLD | 2024 | ~$4.25M |
| Casgevy (exagamglogene autotemcel) | Ex vivo CRISPR | SCD, beta-thal | 2023-24 | $2.2M |
| Zevaskyn (prademagene zamikeracel) | Lentiviral | RDEB | 2025 | TBD |

### Immunogenicity: The Pre-Existing Antibody Problem
**The single largest biological barrier to AAV gene therapy:**
- **AAV2 seroprevalence:** ~59% globally (86% in Chinese populations).
- **AAV5 seroprevalence:** ~35% globally (ranges from 6% in UK to 52% in South Africa).
- **AAV9 seroprevalence:** ~46-58% globally (17% in some European cohorts, 56% in China).
- Seropositive patients are **excluded from treatment.** They simply cannot receive AAV gene therapy.
- After a single AAV dose, patients develop titers of **1:102,400 to 1:819,200** -- making redosing with the same serotype impossible.
- **No AAV gene therapy can be given twice.** This is a one-shot treatment with no second chances if it fails.

### Safety Concerns (2024-2025)
- **Sarepta reported 3 patient deaths** from acute liver failure following Elevidys (AAV-based DMD gene therapy) in 2025.
- Bluebird Bio's Skysona: **Hematologic malignancies in 10 of 67 (15%) clinical trial participants** (MDS/AML), prompting FDA restrictions. This is an insertional mutagenesis risk inherent to lentiviral vectors.
- Bluebird Bio **withdrew from Europe** entirely in 2021 due to inability to negotiate pricing. The company ultimately **sold itself to private equity for ~$30 million** in February 2025, a fraction of its former multi-billion-dollar valuation.
- **Pfizer abandoned Beqvez** (hemophilia B gene therapy) in February 2025, citing lack of patient and physician interest, despite FDA approval.

### Honest Limitations
1. **Cargo limit.** AAV can carry only ~4.7 kb. Many disease-relevant genes exceed this (dystrophin full-length: 11.1 kb; CFTR: 4.4 kb barely fits). Dual-AAV strategies exist but reduce efficiency.
2. **Pre-existing immunity excludes 30-60% of patients** depending on serotype and geography.
3. **No redosing.** The immune response to a first dose prevents a second dose of the same serotype.
4. **Cost is unsustainable.** $2-4 million per dose strains any healthcare system. The Bluebird Bio collapse demonstrates that even approved gene therapies can fail commercially.
5. **Durability is uncertain.** In non-dividing cells (neurons, cardiomyocytes), AAV episomes may persist long-term. In dividing cells (hepatocytes, hematopoietic cells), transgene expression can decline. Whether "one-time cure" truly lasts a lifetime is unknown for most products.
6. **Hepatotoxicity and inflammation.** Systemic AAV delivery at high doses triggers liver inflammation. Corticosteroid pretreatment is standard but imperfect.
7. **Manufacturing is extraordinarily complex** and not easily scalable. Each batch requires viral vector production in specialized facilities.

### Key Companies
Novartis (Zolgensma), Spark/Roche (Luxturna), Sarepta (Elevidys), BioMarin, Bluebird Bio (acquired by Carlyle/SK Capital), UniQure, Ultragenyx, Abeona.

---

## 4.5 Base Editing and Prime Editing

### Mechanism
**Base editors** chemically convert one DNA base to another without making double-strand breaks (DSBs):
- Cytosine base editors (CBE): C-G to T-A.
- Adenine base editors (ABE): A-T to G-C.
- Together, they can correct ~30% of known pathogenic point mutations.

**Prime editors** use a reverse transcriptase fused to a Cas9 nickase, guided by a prime editing guide RNA (pegRNA) that encodes the desired edit. They can make all 12 types of point mutations, small insertions, and small deletions -- without DSBs or donor DNA templates. Theoretically corrects **~89% of known pathogenic mutations**.

### Clinical Trials (2024-2025)

**Beam Therapeutics (Base Editing):**
- **BEAM-101** for sickle cell disease: Phase 1/2 BEACON trial. First patient dosed January 2024. Base edit targets the BCL11A erythroid enhancer to reactivate fetal hemoglobin.
- By December 2024, data from **7 patients** showed: >60% HbF induction, <40% HbS reduction, resolution of anemia in all patients.
- As of 2025, **>40 patients** treated in BEACON trial with robust engraftment and rising fetal hemoglobin.
- Key advantage over Casgevy: base editing avoids double-strand breaks, theoretically reducing chromosomal rearrangement risk.

**Prime Medicine (Prime Editing):**
- **PM359** for X-linked chronic granulomatous disease (CGD): First prime editor to enter the clinic. FDA cleared IND in May 2024.
- First-ever clinical data reported: a single dose of PM359 **restored NADPH oxidase activity** in a patient with CGD -- proof-of-concept for prime editing in humans.
- Pipeline: Alpha-1 antitrypsin deficiency (liver/lung disease) -- IND filing expected 2026.

### Off-Target Concerns
- **CBE (cytosine base editors):** Studies in embryos showed **up to 20x higher unpredictable off-target editing** compared to ABE. This includes bystander editing at nearby cytosines within the editing window.
- **ABE (adenine base editors):** Lower off-target DNA editing but can cause RNA off-target deamination.
- **Prime editors:** Generally lower off-target rates than base editors or nuclease Cas9, but the technology is newer and less characterized.
- **NIH-led base editing trial for X-linked CGD was paused in 2025** after a patient experienced a severe adverse event -- underscoring that even "DSB-free" editing is not risk-free.
- **Guide-dependent off-targets** at similar genomic sequences remain a concern for all CRISPR-derived editors.

### Development Timeline
- Base/prime editing clinical candidates are **5-10 years behind CRISPR nucleases** in maturity.
- First approvals are plausibly expected **2028-2030** for base editors, later for prime editors.
- Most current programs are ex vivo (cells edited outside the body); in vivo base/prime editing is still preclinical.

### Honest Limitations
1. **Delivery is the same problem as CRISPR.** Lipid nanoparticles for liver; ex vivo for blood. Reaching other tissues in vivo remains unsolved.
2. **Editing efficiency.** Prime editing is less efficient than base editing, which is less efficient than nuclease Cas9 cutting. The precision-efficiency tradeoff is real.
3. **Size.** Base editor and prime editor proteins are very large (~5.5 kb for ABE, ~6.3 kb for prime editors), making AAV packaging difficult. Dual-AAV or mRNA delivery is required.
4. **Limited clinical data.** As of early 2026, fewer than 50 patients worldwide have been treated with base editors; single-digit for prime editors.
5. **No long-term safety data.** The oldest base-editing patients are ~2 years post-treatment.

### Key Companies
Beam Therapeutics, Prime Medicine, Verve Therapeutics (base editing for cardiovascular), David Liu Lab (academic inventor of both technologies).

---

## 4.6 CRISPR Therapeutics

### Mechanism
CRISPR-Cas9 creates targeted double-strand breaks in DNA. The cell then repairs the break via non-homologous end joining (NHEJ, producing insertions/deletions to disrupt genes) or homology-directed repair (HDR, to insert specific sequences). Cas9 is guided by a single guide RNA (sgRNA) complementary to the target.

### Casgevy: The First CRISPR Medicine
- **Casgevy (exagamglogene autotemcel):** Approved UK November 2023; US December 2023 (SCD); US January 2024 (beta-thalassemia). Developed by Vertex/CRISPR Therapeutics.
- **Mechanism:** Ex vivo editing of patient's own hematopoietic stem cells. CRISPR disrupts BCL11A enhancer in erythroid cells, reactivating fetal hemoglobin to compensate for defective adult hemoglobin.
- **Price:** $2.2 million.
- **Process:** Requires stem cell mobilization, leukapheresis, myeloablative conditioning (chemotherapy to destroy existing bone marrow), cell editing, and reinfusion. Hospitalization for weeks to months.

### Ex Vivo vs. In Vivo CRISPR

**Ex Vivo (Current Standard):**
- Remove cells from patient -> edit in lab -> return to patient.
- Works for: blood disorders (SCD, thalassemia, cancers).
- Cannot reach: liver, brain, heart, kidney, lung, solid tumors.
- Requires myeloablative conditioning for hematopoietic therapies -- chemotherapy with significant toxicity.

**In Vivo (Frontier):**
- Deliver CRISPR components directly into the body, typically via LNPs to the liver.
- **Intellia Therapeutics -- NTLA-2001** for ATTR amyloidosis: Groundbreaking Phase I data showed one-time IV infusion reduced serum TTR by ~90%. Global Phase III initiated January 2025.
  - **CRITICAL SETBACK (October 2025):** An 80-year-old patient died following Grade 4 liver transaminases and increased bilirubin. FDA placed clinical hold on NTLA-2001 and related trials.
- **Intellia -- NTLA-2002** for hereditary angioedema: 86% reduction in kallikrein at higher dose. 8 of 11 patients attack-free for 16+ weeks. Phase III initiated January 2025.
- **Verve Therapeutics -- VERVE-102** for cardiovascular disease: LNP-delivered base editor targeting PCSK9 in liver. 14 patients dosed; highest dose showed 59% LDL cholesterol reduction. No serious adverse events. **Verve acquired by Eli Lilly in June 2025.**

### Number of CRISPR Clinical Trials
- As of 2025, **dozens of CRISPR clinical trials are active** worldwide, spanning oncology (CAR-T with CRISPR-edited cells), blood disorders, liver diseases, eye diseases, and infectious diseases.
- CRISPR Therapeutics has established a proprietary LNP delivery platform for liver-targeted in vivo editing.

### Honest Limitations
1. **Double-strand breaks are dangerous.** DSBs can cause large deletions, chromosomal rearrangements, and chromothripsis. The long-term cancer risk from DSBs in billions of cells is unknown.
2. **Off-target editing.** Cas9 can cut at sites with partial complementarity to the guide RNA. Whole-genome sequencing of edited cells is not routinely feasible at clinical scale.
3. **In vivo delivery is liver-only.** LNPs deliver efficiently to hepatocytes, but no clinically validated non-viral delivery exists for brain, muscle, heart, kidney, or lung.
4. **Ex vivo therapies require myeloablative conditioning** -- effectively chemotherapy -- which carries its own mortality risk and limits applicability to otherwise healthy patients.
5. **Cost and complexity.** Casgevy at $2.2M per patient, requiring weeks of hospitalization, limits global access. The entire SCD population of sub-Saharan Africa (~5 million patients) is economically unreachable.
6. **Intellia's patient death** in late 2025 highlights that in vivo CRISPR editing in older, frailer patients carries hepatotoxicity risks that may limit the treatable population.

### Key Companies
CRISPR Therapeutics, Vertex (Casgevy partner), Intellia Therapeutics, Editas Medicine, Caribou Biosciences, Verve Therapeutics (now Eli Lilly).

---

## 4.7 RNA Therapeutics Beyond ASOs

### 4.7.1 Small Interfering RNA (siRNA)

**Mechanism:** Double-stranded RNA (~21 nt) that harnesses the endogenous RNA interference (RNAi) pathway. The guide strand loads into RISC (RNA-induced silencing complex), which then catalytically degrades complementary mRNA. One siRNA molecule can destroy hundreds of mRNA copies.

**Approved siRNA Drugs (as of March 2025): 6 Alnylam-discovered products**

| Drug | Target Gene | Indication | Year | Delivery |
|------|------------|------------|------|----------|
| Patisiran (Onpattro) | TTR | hATTR polyneuropathy | 2018 | LNP IV |
| Givosiran (Givlaari) | ALAS1 | Acute hepatic porphyria | 2019 | GalNAc SC |
| Lumasiran (Oxlumo) | HAO1 | Primary hyperoxaluria | 2020 | GalNAc SC |
| Inclisiran (Leqvio) | PCSK9 | Hypercholesterolemia | 2021 | GalNAc SC |
| Vutrisiran (Amvuttra) | TTR | hATTR with cardiomyopathy | 2022 | GalNAc SC |
| Fitusiran (Qfitlia) | Antithrombin | Hemophilia A/B | 2025 | GalNAc SC |

**Key advantages over ASOs:**
- Catalytic mechanism (one siRNA destroys many mRNAs) = more potent at lower doses.
- GalNAc conjugation enables subcutaneous dosing every 3-6 months for some products.
- Inclisiran: twice-yearly injection for cholesterol -- transformative for patient compliance.

**Alnylam's "2030 Strategy":**
- Projected multiple products with >$1 billion peak revenue each (Amvuttra, Leqvio, Qfitlia).
- Pipeline includes ALN-APP for Alzheimer's (targeting APP production in liver).

**Limitations:**
- **Liver-centric.** GalNAc delivery is hepatocyte-specific. siRNA delivery to non-liver tissues remains largely unsolved.
- **No permanent effect.** Requires repeated dosing (though at 3-6 month intervals for GalNAc products).
- **Cannot upregulate genes** -- only silence them.

### 4.7.2 mRNA Therapeutics (Beyond COVID)

**Mechanism:** Synthetic mRNA is delivered (typically via LNPs) into cells, where ribosomes translate it into protein. The mRNA is transient (days to weeks), producing protein without altering the genome.

**Post-COVID landscape:**
The COVID-19 mRNA vaccines (Pfizer/BioNTech's Comirnaty, Moderna's Spikevax) validated the platform spectacularly, generating >$100 billion in combined revenue. The question: can mRNA do more than vaccines?

**Active frontiers:**

1. **Cancer vaccines (personalized neoantigens):**
   - **Moderna/Merck -- mRNA-4157 (intismeran autogene) + pembrolizumab:** Phase 2b KEYNOTE-942 in resected melanoma. **5-year follow-up (January 2026): 49% reduction in risk of recurrence or death vs. pembrolizumab alone.** The longest-term evidence for individualized mRNA neoantigen therapy.
   - 8 Phase II/III trials underway across melanoma, NSCLC, bladder, and renal cell carcinoma.
   - Each vaccine is **completely individualized** -- patient's tumor is sequenced, neoantigens identified, mRNA synthesized. Turnaround: ~6-8 weeks.
   - First commercial mRNA cancer vaccine approval anticipated **~2029**.

2. **Protein replacement therapy:**
   - Moderna's mRNA-3927 for propionic acidemia (rare metabolic disorder) -- Phase I/II.
   - mRNA encoding CFTR for cystic fibrosis (Translate Bio/Sanofi) -- early clinical.
   - Challenge: repeated dosing needed, immunogenicity of LNPs increases with repeated administration.

3. **Rare disease (enzyme replacement):**
   - mRNA could potentially replace IV enzyme infusions for lysosomal storage diseases.

**Limitations:**
- **Transient expression.** mRNA degrades within days. Chronic diseases require repeated dosing.
- **LNP immunogenicity.** Anti-PEG antibodies develop with repeated LNP dosing, potentially reducing efficacy and causing allergic reactions.
- **Liver tropism.** Standard LNPs preferentially deliver to liver. Lung and other tissue targeting is under development but not clinically validated.
- **Cold chain.** mRNA vaccines require -20 degrees C to -70 degrees C storage (formulation dependent).

### 4.7.3 Self-Amplifying RNA (saRNA)

**Mechanism:** saRNA encodes both the therapeutic protein and an RNA-dependent RNA polymerase (derived from alphaviruses). Once delivered, the RNA replicates itself inside cells, amplifying protein production at much lower initial doses.

**Milestone:** ARCT-154 (CSL/Arcturus Therapeutics) -- first saRNA vaccine approved (Japan, November 2023; EU, 2025) for COVID-19.
- **Demonstrated superior immunogenicity vs. conventional mRNA (Comirnaty) at one-sixth the dose** (5 ug vs. 30 ug) at 12 months.
- The dose advantage could dramatically reduce manufacturing costs and improve access.

**Limitations:**
- **Innate immune activation.** saRNA's replication intermediate (dsRNA) potently activates innate immunity, which can limit translation and cause reactogenicity.
- **Very early clinical stage** beyond COVID vaccines.
- **Size.** saRNA constructs are ~10 kb (much larger than conventional mRNA at ~2-4 kb), making formulation and delivery more challenging.

### Key Companies
Alnylam, Arrowhead Pharmaceuticals, Dicerna/Novo Nordisk, Moderna, BioNTech, CureVac, Arcturus Therapeutics, Translate Bio/Sanofi.

---

## 4.8 Cell Therapies Beyond CAR-T

### 4.8.1 iPSC-Derived Cell Therapies

**Mechanism:** Induced pluripotent stem cells (iPSCs) are adult cells reprogrammed to an embryonic-like state, then differentiated into any desired cell type. They enable "off-the-shelf" allogeneic cell products -- a single iPSC line can theoretically produce unlimited doses for any patient.

**Clinical landscape (as of December 2024):**
- **83 human PSC-derived products** undergoing testing in **115 clinical trials** worldwide.
- **>1,200 patients** dosed with hPSC products to date, with >10^11 clinically administered cells.
- **No generalizable safety concerns** reported so far (no confirmed teratoma formation in any trial).

**Key milestones (2024-2025):**
- **Parkinson's disease:** Phase I/II trial reported iPSC-derived dopaminergic progenitors survived transplantation, produced dopamine, and **did not form tumors** (April 2025).
- **Retinal degeneration:** OpCT-001, first iPSC-based therapy for primary photoreceptor diseases, FDA IND clearance September 2024.
- **Lupus:** iPSC-derived CAR-T for systemic lupus erythematosus received FDA RMAT designation, April 2025.
- **ALS, spinal cord injury, Parkinson's:** Three iPSC-based therapies received FDA IND clearance in June 2025.

**Limitations:**
- **Immune rejection.** Allogeneic iPSC products may require immunosuppression or HLA-matching.
- **Tumorigenicity risk.** Despite no confirmed cases, the theoretical risk of residual undifferentiated cells forming teratomas mandates extensive safety testing.
- **Differentiation quality control.** Ensuring homogeneous, functional cell populations at scale is technically demanding.
- **No FDA-approved iPSC therapy yet** (as of early 2026).

### 4.8.2 Mesenchymal Stem/Stromal Cells (MSCs)

- **Ryoncil (remestemcel-L):** FDA approved December 2024 -- **first MSC approval** for pediatric steroid-refractory acute graft-versus-host disease (SR-aGVHD).
- MSCs exert immunomodulatory effects through paracrine signaling rather than engraftment.
- Hundreds of clinical trials for conditions ranging from GVHD to heart failure to COVID-19 ARDS.
- **Criticism:** Many MSC trials have shown inconsistent results. The field has been plagued by poorly controlled studies and hype exceeding evidence.

### 4.8.3 Regulatory T Cells (Tregs)

- **69 Treg clinical trials** active across autoimmune diseases and transplantation (as of 2025).
- **CAR-Treg therapies** now in first-in-human trials:
  - HLA-A2-specific CAR Tregs for kidney transplant rejection (Sangamo, Phase I/IIa).
  - Citrullinated vimentin-specific CAR Tregs for rheumatoid arthritis and hidradenitis suppurativa (Sonoma Therapeutics).
  - CD6-specific CAR Tregs for GVHD.
  - Quell Therapeutics: CAR Tregs for liver transplant rejection (Phase I/IIa).
- **Goal:** Restore immune tolerance without broad immunosuppression.
- **Limitations:** Treg stability (risk of conversion to effector T cells), manufacturing complexity, lack of validated potency assays, and very early clinical stage.

### 4.8.4 Tumor-Infiltrating Lymphocytes (TILs)
- **Amtagvi (lifileucel):** FDA approved February 2024 -- first TIL therapy, for unresectable/metastatic melanoma.
- Autologous TILs expanded from patient's tumor, showing durable responses in heavily pretreated melanoma.

### Key Companies
FUJIFILM Cellular Dynamics, BlueRock Therapeutics (Bayer), Fate Therapeutics, Century Therapeutics, Iovance Biotherapeutics (TILs), Sonoma Therapeutics, Quell Therapeutics, Sangamo, Tr1X Bio.

---

## 4.9 Drug Delivery

### The Central Problem
**Delivery is the rate-limiting step for nearly every advanced therapeutic modality.** We can design exquisite gene editors, ASOs, siRNAs, and mRNA constructs -- but getting them to the right cells in the right tissue at the right dose, without toxicity, remains the fundamental unsolved challenge.

### 4.9.1 Lipid Nanoparticles (LNPs)

**How they work:** LNPs encapsulate nucleic acid payloads in a lipid shell composed of ionizable lipids, helper lipids, cholesterol, and PEG-lipid. The ionizable lipid (pKa ~6.2) remains neutral at physiological pH but becomes cationic in acidic endosomes, enabling endosomal escape.

**What they can reach:**
- **Liver:** The default. After IV injection, LNPs opsonize with ApoE in blood and are taken up by hepatocytes via LDL receptor. ~80-90% of standard LNPs accumulate in liver.
- **Spleen/immune cells:** Some formulations (e.g., with different lipid compositions or charge ratios) shift tropism to spleen.
- **Muscle (local):** Intramuscular injection for vaccines.
- **Lung:** Inhalation or specific lipid formulations (SORT technology) can target lung.

**What they cannot reliably reach:**
- **Brain:** The BBB blocks standard LNPs. Recent advances (2024-2025):
  - Peptide-functionalized LNPs (RVG29, T7, mApoE peptides) have shown improved neuronal transfection in animal models.
  - Mount Sinai developed an LNP platform that delivers mRNA to the brain through the BBB in mice.
  - **None validated in human clinical trials yet.**
- **Heart, kidney, pancreas:** Minimal delivery from systemic administration.
- **Specific cell types within tissues:** Achieving true cell-type specificity (e.g., only astrocytes, only cardiomyocytes, only podocytes) remains largely aspirational.

**Key limitation:** Anti-PEG antibodies develop with repeated dosing, potentially causing accelerated blood clearance and allergic reactions.

### 4.9.2 AAV Vectors (as Delivery Vehicles)

**Tissue tropism by serotype:**

| Serotype | Primary Tropism |
|----------|----------------|
| AAV1 | Muscle, CNS |
| AAV2 | Broad (retina, liver, CNS) |
| AAV5 | Liver, lung, CNS |
| AAV8 | Liver, muscle |
| AAV9 | Broad (CNS, muscle, heart, liver) |
| AAVrh74 | Muscle |

**Advantages:** Efficient transduction of non-dividing cells, long-term expression, multiple tissue tropisms. **BBB-crossing:** AAV9 and AAVrh10 cross the BBB to some degree, enabling CNS gene therapy (Zolgensma uses AAV9).

**Limitations:** Pre-existing antibodies (30-60%), immunogenicity, no redosing, cargo limit (4.7 kb), manufacturing complexity, hepatotoxicity at high doses.

### 4.9.3 Exosomes / Extracellular Vesicles

- Natural cell-derived vesicles (30-150 nm) that can carry proteins, RNA, and lipids.
- **BBB-crossing potential:** Exosomes have innate ability to traverse the BBB due to surface markers that enable transcytosis.
- Studies show brain endothelial cell-derived exosomes can transfect neuronal cells.
- **Advantages:** Low immunogenicity, biocompatibility, natural BBB penetration.
- **Limitations:** Extremely difficult to manufacture at scale with consistent quality. Loading efficiency is low. Heterogeneous populations. **No exosome therapy is FDA-approved.** Regulatory pathway unclear.

### 4.9.4 GalNAc Conjugation
- N-acetylgalactosamine conjugated to oligonucleotides enables receptor-mediated uptake by hepatocytes via asialoglycoprotein receptor (ASGPR).
- **The most successful targeted delivery platform in nucleic acid therapeutics.** All recent Alnylam siRNA approvals use GalNAc.
- **Limitation:** Liver only. ASGPR is hepatocyte-specific.

### 4.9.5 Other Approaches
- **Antibody-oligonucleotide conjugates:** Linking ASOs/siRNAs to antibodies for cell-specific delivery (muscle, immune cells).
- **Focused ultrasound + microbubbles:** Temporarily opens the BBB for ~4-6 hours, allowing drug entry. Clinical trials ongoing for brain tumors.
- **Intrathecal/intracisternal injection:** Bypasses BBB but is invasive.
- **Intranasal delivery:** Some evidence for nose-to-brain transport, but efficiency is very low.

### The Delivery Gap: What We Still Cannot Do (2026)
1. **Deliver to the brain systemically** at therapeutic doses without invasive procedures.
2. **Reach specific cell types** (e.g., only hepatic stellate cells, only dopaminergic neurons) after systemic injection.
3. **Redose viral vectors** after immune response to first dose.
4. **Deliver large payloads (>5 kb)** to non-liver tissues via non-viral means.
5. **Target solid tumors** with cell therapies or gene editors in vivo.

---

## 4.10 Vaccines

### The Post-COVID Speed Revolution

**COVID-19 demonstrated unprecedented vaccine development speed:**
- Viral sequence published: January 10, 2020.
- First mRNA vaccine candidate (Moderna) batch produced: February 7, 2020 (28 days).
- First-in-human dosing: March 16, 2020 (65 days).
- Emergency Use Authorization (Pfizer/BioNTech): December 11, 2020 (326 days from sequence).
- In those 326 days, **>70 million COVID cases and 1.6 million deaths** were recorded.

**CEPI's 100 Days Mission:** Compress safe vaccine development to 100 days from pathogen identification. Analysis suggests current innovations might reduce the 326-day timeline by ~25%, to ~250 days. True 100-day timelines remain aspirational.

**mRNA platform advantage:** Sequence-to-candidate in weeks. Manufacturing is template-agnostic (same LNP process for any mRNA sequence).

### Hard-to-Vaccinate Pathogens

#### HIV
- **40+ years, zero effective vaccines, ~$18 billion spent.**
- **10 efficacy trials conducted; only RV144 (Thailand, 2009) showed any protection: 31.2% -- insufficient for deployment.**
- Fundamental challenges:
  - Extreme viral genetic diversity (HIV mutates ~1 million times faster than human genome).
  - Rapid establishment of latent reservoir within days of infection.
  - HIV targets and destroys the very immune cells (CD4+ T cells) vaccines try to activate.
  - Broadly neutralizing antibodies (bnAbs) take **years** to develop naturally in infected individuals; no vaccine has successfully induced them.
  - The virus's envelope glycoprotein is shielded by a glycan shield and conformational masking.
- **Current approaches:** Germline-targeting immunogens (IAVI/Scripps), sequential boosting to guide B cell maturation, mRNA-based HIV vaccines (Moderna Phase I), bnAb cocktail prophylaxis.
- **Honest assessment:** An effective HIV vaccine may still be >10 years away, if achievable at all.

#### Tuberculosis
- **BCG (1921):** The only licensed TB vaccine. Efficacy ranges from **0-80%** depending on population and study -- highly inconsistent, particularly poor in adult pulmonary TB.
- **M72/AS01E:** Most advanced candidate. Phase 2b showed **49.7% efficacy at 3 years** in latently infected adults. **Phase 3 trial (20,000 participants across 5 countries) fully enrolled as of April 2025.** Results expected ~2028.
- **BioNTech BNT164:** mRNA TB vaccine in Phase I (120 adults, multiple antigens). First results expected 2025.
- TB kills ~1.3 million people/year. A 50% effective vaccine would still save hundreds of thousands of lives.

#### Malaria
- **RTS,S (Mosquirix):** First malaria vaccine, WHO-recommended 2021. Efficacy: ~30-40% over 4 years, waning with time.
- **R21/Matrix-M (Oxford/Serum Institute):** WHO-recommended October 2023. Phase 3 efficacy: **75% (seasonal), 68% (perennial)** at 1 year with 3-dose regimen. **Substantially better than RTS,S.**
- By 2025, **24+ countries** have introduced malaria vaccines; 10+ million children targeted annually.
- WHO estimates malaria vaccines could **prevent ~500,000 child deaths by 2035** if fully scaled.
- **438,000 African children died from malaria in 2024** -- the urgency remains extreme.

### Cancer Vaccines

**Therapeutic cancer vaccines (not preventive):**
- **mRNA-4157/V940 (Moderna/Merck):** Personalized neoantigen vaccine + pembrolizumab. 5-year data in melanoma: **49% reduction in recurrence/death.** 8 trials across tumor types. Regulatory submission anticipated 2026.
- **Autogene cevumeran (BioNTech/Genentech):** Personalized mRNA vaccine for pancreatic cancer. Phase II trial in resected patients showing neoantigen-specific T cell responses correlated with non-recurrence.
- **>120 RNA-based cancer vaccine clinical trials** active as of 2025.
- First commercial approval expected **~2029.**

**Limitations of cancer vaccines:**
- Each vaccine must be individualized (tumor sequencing, neoantigen prediction, custom manufacturing).
- Manufacturing time: 6-8 weeks per patient (too slow for rapidly progressing cancers).
- Efficacy in adjuvant (post-surgery) setting is clearer than in advanced/metastatic disease.
- Neoantigen prediction algorithms are imperfect -- not all predicted neoantigens are immunogenic.
- Tumor immune evasion can render even good immune responses ineffective.

### Vaccine Success Rates
- **Vaccines for infectious diseases have the highest clinical trial success rate of any modality: ~33%** from Phase I to approval, compared to ~10-14% for drugs overall and ~3.4% for oncology drugs.

### Key Companies
Moderna, BioNTech, Pfizer, GSK, Sanofi, Merck, AstraZeneca, Novavax, Arcturus Therapeutics, CSL Seqirus, Oxford/Serum Institute of India.

---

## 4.11 Cross-Cutting Metrics: The Honest Scorecard

### Clinical Trial Success Rates (Phase I to Approval)

| Modality | Success Rate | Notes |
|----------|-------------|-------|
| All drugs (all modalities) | 10-14% | BIO/QLS, 2011-2020 data |
| Small molecules (all indications) | ~8-12% | Below average due to selectivity issues |
| Small molecules (oncology) | ~3.4% | Worst-performing category |
| Small molecules (rare disease) | ~25% | Orphan drug incentives, clearer endpoints |
| Biologics (mAbs) | ~15-25% | Better target specificity |
| Vaccines (infectious disease) | ~33% | Highest of any modality |
| Cell & gene therapies | High phase transition in late stages | But disproportionate clinical holds |
| ASOs/siRNA | Limited data | ~10 ASOs + 6 siRNAs approved over ~25 years |

### Average Development Timeline (Discovery to Approval)

| Modality | Typical Timeline |
|----------|-----------------|
| Small molecule | 10-15 years |
| Monoclonal antibody | 8-12 years |
| ASO/siRNA | 8-15 years |
| Gene therapy | 10-20+ years |
| CRISPR therapy | 8-15 years (still early) |
| mRNA vaccine (pandemic) | 326 days (COVID) |
| mRNA vaccine (standard) | 5-10 years |
| Cell therapy (CAR-T) | 8-12 years |

### Cost Per Approved Drug

| Component | Typical Cost |
|-----------|-------------|
| Preclinical discovery | $10-50M |
| Phase I | ~$25M |
| Phase II | ~$60M |
| Phase III | ~$350M |
| Total (including failures, capital) | $0.7-2.6B per approved drug |

### Per-Dose/Per-Treatment Cost to Patient

| Modality | Cost Range |
|----------|-----------|
| Small molecule (generic) | $0.01-$10/dose |
| Small molecule (branded) | $100-$10,000/month |
| Monoclonal antibody | $10,000-$200,000/year |
| siRNA (GalNAc, SC) | $200,000-$400,000/year |
| ASO (intrathecal) | ~$375,000/year (Spinraza) |
| CAR-T therapy | $375,000-$475,000 (drug only); $500K-$1M+ total |
| Gene therapy (AAV) | $850K-$4.25M (one-time) |
| CRISPR therapy (Casgevy) | $2.2M (one-time) |

---

## 4.12 Synthesis: What Works, What Doesn't, and Where the Gaps Are

### What Works
1. **Small molecules for well-defined enzymatic targets** remain the most efficient, scalable, orally available therapeutic modality. When you have a good target with a druggable pocket, nothing beats a pill.
2. **Monoclonal antibodies for extracellular targets** offer unmatched specificity. Checkpoint inhibitors (Keytruda) have transformed oncology. Anti-inflammatory mAbs (Dupixent, Skyrizi) have transformed dermatology and pulmonology.
3. **GalNAc-siRNA for liver gene silencing** is the most elegant targeted delivery solution in all of nucleic acid therapeutics. Subcutaneous injection every 3-6 months to durably silence any liver-expressed gene.
4. **mRNA vaccines** have been validated as the fastest-responding platform for emerging infectious diseases.
5. **Ex vivo gene editing (CRISPR, base editing)** for blood disorders has achieved transformative clinical results -- functional cures for sickle cell disease and beta-thalassemia.

### What Doesn't Work (Yet)
1. **Anything requiring delivery to the brain** without invasive procedures. The BBB remains the most formidable barrier in all of drug delivery.
2. **CAR-T for solid tumors.** Despite enormous investment, no CAR-T therapy has shown meaningful efficacy in solid tumors.
3. **Gene therapy as a commercial business.** Bluebird Bio's collapse, Pfizer's abandonment of Beqvez, and multiple program terminations show that $2-4M one-time therapies for small patient populations may be commercially unviable under current healthcare economics.
4. **HIV vaccines.** After four decades and $18+ billion, no effective vaccine exists.
5. **In vivo gene editing beyond the liver.** No non-viral delivery system has achieved therapeutically relevant gene editing in non-liver tissues in humans.

### The Five Biggest Gaps
1. **The delivery gap:** We have the editors, we have the targets, but we cannot get therapies to most tissues in the body. Solving extrahepatic delivery would unlock dozens of diseases overnight.
2. **The cost gap:** Gene therapies at $2-4M/patient, CAR-T at $500K+/patient, and siRNAs at $200K+/year are inaccessible to most of the world's patients. The diseases with the greatest global burden (malaria, TB, sickle cell) affect populations least able to pay.
3. **The solid tumor gap:** Every modality that works in liquid tumors (CAR-T, bispecifics, checkpoint inhibitors) has reduced efficacy in the immunosuppressive solid tumor microenvironment.
4. **The CNS gap:** Neurodegeneration, psychiatric disease, and brain tumors collectively represent enormous unmet need, yet drug delivery to the brain remains primitive (intrathecal injection, or nothing).
5. **The durability gap:** For non-integrating therapies (AAV gene therapy, ASOs, siRNAs, mRNA), how long effects truly last -- and what happens when they wear off -- remains uncertain for most products.

---

*Data in this chapter reflects information available through early 2026. Clinical trial results, regulatory decisions, and company status may have changed since compilation. All success rates are historical averages and may not predict future outcomes.*

---

**Sources used in compilation:**

- [2024 Novel Small Molecule FDA Drug Approvals - Drug Hunter](https://drughunter.com/articles/2024-novel-small-molecule-fda-drug-approvals)
- [2025 Novel Small Molecule FDA Drug Approvals - Drug Hunter](https://drughunter.com/articles/2025-novel-small-molecule-fda-drug-approvals)
- [FDA 2024 analysis: Small molecule resilience - Drug Discovery Trends](https://www.drugdiscoverytrends.com/4-trends-in-fda-novel-approvals-in-2024/)
- [BIO Clinical Development Success Rates 2011-2020](https://www.bio.org/clinical-development-success-rates-and-contributing-factors-2011-2020)
- [Dynamic clinical trial success rates - Nature Communications](https://www.nature.com/articles/s41467-025-64552-2)
- [Benchmarking R&D success rates - ScienceDirect](https://www.sciencedirect.com/science/article/pii/S1359644625000042)
- [Clinical trial costs - JAMA Network Open](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2828689)
- [Biologics Market Size - Towards Healthcare](https://www.towardshealthcare.com/insights/biologics-market-size)
- [Antibodies to watch in 2025 - PubMed](https://pubmed.ncbi.nlm.nih.gov/39711140/)
- [Top 10 highest grossing drugs in 2024](https://druganddeviceworld.com/2025/03/04/top-10-highest-grossing-drugs-in-2024-by-sales/)
- [CAR-T cell therapies: patient access and affordability - PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11959894/)
- [CAR-T Cell Therapy Market Research 2024-2025 - GlobeNewsWire](https://www.globenewswire.com/news-release/2025/01/03/3003845/28124/en/CAR-T-Cell-Therapy-Market-Research-2024-2025)
- [Approved CAR-T therapies have reproducible efficacy - PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11305028/)
- [A Collection of Approved Antisense Therapeutic Drugs 2024 - BioSyn](https://www.biosyn.com/tew/A-Collection-of-Approved-Antisense-Therapeutic-Drugs-2024.aspx)
- [Mechanisms of Action of FDA-Approved ASO Drugs - PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11695194/)
- [Ionis Innovation Day - Ionis Pharmaceuticals](https://ir.ionis.com/news-releases/news-release-details/ionis-showcases-transformational-medicines-and-industry-leading)
- [SPINRAZA Dosing & Administration](https://www.spinrazahcp.com/en_us/home/starting-spinraza/dosing-and-administration.html)
- [List of FDA Approved Cell and Gene Therapy Products - BioInformant](https://bioinformant.com/u-s-fda-approved-cell-and-gene-therapies/)
- [Top FDA Gene and Cell Therapy News 2025 - CGTlive](https://www.cgtlive.com/view/top-fda-gene-cell-therapy-news-2025-year-end-recap)
- [Global Seroprevalence of Pre-existing Immunity Against AAV5 - PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC9063149/)
- [Global seroprevalence of NAbs against AAV serotypes - PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11253686/)
- [AAV-Based Gene Therapy Opportunities and Risks - PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12428605/)
- [Bluebird Bio sells itself to private equity - CNBC](https://www.cnbc.com/2025/02/21/bluebird-bio-gene-therapy-sells-itself-to-carlyle-and-sk-capital.html)
- [FDA restricts Skysona after blood cancer reports - Fierce Pharma](https://www.fiercepharma.com/pharma/fda-restricts-bluebird-bio-gene-therapy-skysona-after-blood-cancer-reports)
- [Pfizer ends Beqvez commercialization](https://www.drugdiscoverynews.com/is-aav-gene-therapy-at-a-turning-point-16755)
- [Base and Prime Editing Timelines 2026-2030 - Biotech Industry Examiner](https://biotech.industryexaminer.com/base-prime-editing-timelines-patient-impact/)
- [First-Ever Prime-Editing Therapy in Patient - CRISPR Medicine News](https://crisprmedicinenews.com/news/first-ever-prime-editing-therapy-shows-safety-and-efficacy-in-patient-with-chronic-granulomatous-dis/)
- [Gene Editing Marches On - GEN News](https://www.genengnews.com/topics/genome-editing/gene-editing-marches-on-despite-missed-beats/)
- [CRISPR Clinical Trials 2025 Update - IGI](https://innovativegenomics.org/news/crispr-clinical-trials-2025/)
- [Intellia patient death report - Inside Precision Medicine](https://www.insideprecisionmedicine.com/topics/precision-medicine/reporters-notebook-is-intellias-patient-death-the-nail-in-the-coffin-for-cas9/)
- [Verve VERVE-102 data - TCTMD](https://www.tctmd.com/news/topline-data-point-promise-verve-102-gene-editing-therapy)
- [Alnylam FDA Approval Qfitlia](https://investors.alnylam.com/press-release?id=28901)
- [Alnylam 2030 Strategy](https://investors.alnylam.com/press-release?id=29491)
- [Moderna/Merck 5-Year mRNA-4157 Data](https://www.merck.com/news/moderna-merck-announce-5-year-data-for-intismeran-autogene-in-combination-with-keytruda-pembrolizumab-demonstrated-sustained-improvement-in-the-primary-endpoint-of-recurrence-free-survival-i/)
- [Self-amplifying RNA vaccine CSL/Arcturus](https://newsroom.csl.com/2024-09-30-Self-Amplifying-mRNA-COVID-19-Vaccine-Demonstrates-Superior-Immune-Response-Compared-with-mRNA-Vaccine-at-12-Months-Post-Vaccination)
- [Pluripotent stem-cell-derived therapies 2025 update - Cell Stem Cell](https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(24)00445-4)
- [Regulatory T cell therapies - Frontiers in Immunology](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1675114/full)
- [Current Landscape of FDA Stem Cell Approvals 2023-2025 - ReproCELL](https://www.reprocell.com/blog/current-landscape-of-fda-stem-cell-approvals-and-trials-2023-2025)
- [Peptide-Functionalized LNPs for Brain Delivery - Nano Letters](https://pubs.acs.org/doi/10.1021/acs.nanolett.4c05186)
- [New LNP Platform Delivers mRNA to Brain - Mount Sinai](https://www.mountsinai.org/about/newsroom/2025/new-lipid-nanoparticle-platform-delivers-mrna-to-the-brain-through-the-blood-brain-barrier)
- [Exosome-powered neuropharmaceutics - J Nanobiotechnology](https://link.springer.com/article/10.1186/s12951-025-03352-8)
- [CEPI 100 Days Mission - NEJM](https://www.nejm.org/doi/full/10.1056/NEJMp2202669)
- [HIV Vaccine Development at a Crossroads - MDPI Vaccines](https://www.mdpi.com/2076-393X/12/9/1043)
- [Malaria vaccines reach children in 17 countries 2024 - WHO](https://www.who.int/news-room/feature-stories/detail/life-saving-malaria-vaccines-reach-children-in-17-endemic-countries-in-2024)
- [R21/Matrix-M Phase 3 trial - The Lancet](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)02511-4/fulltext)
- [M72/AS01E TB Vaccine Phase 3 - STAT News](https://www.statnews.com/2025/04/28/major-tuberculosis-vaccine-trial-completes-enrollment-faster-than-expected/)
- [Current Progress in RNA Cancer Vaccines 2025 - PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12153701/)